Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis-Reference-Cited by-同舟云学术

Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis

Published:2016-12-09 Issue:3 Volume:390 Page:261-268
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Fujimoto Yasuyuki,Azuma Yasu-Taka,Matsuo Yukiko,Kuwamura Mitsuru,Kuramoto Nobuyuki,Miki Mariko,Azuma Naoki,Teramoto Midori,Nishiyama Kazuhiro,Izawa Takeshi,Nakajima Hidemitsu,Takeuchi Tadayoshi

Funder

Grants-in-Aid for Young Scientists (B)

Grant-in-Aid for Scientific Research (B)

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00210-016-1329-0.pdf

Reference30 articles.

1. Azuma YT, Hagi K, Shintani N, Kuwamura M, Nakajima H, Hashimoto H, Baba A, Takeuchi T (2008) PACAP provides colonic protection against dextran sodium sulfate induced colitis. J Cell Physiol 216:111–119

2. Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, Nakajima H, Karow M, Takeuchi T (2010a) Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis 16:1017–1028

3. Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H, Takeuchi T (2010b) PPARα contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10:1261–1267

4. Boirivant M, Fuss IJ, Chu A, Strober W (1998) Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188:1929–1939

5. Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3:521–533

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of serum interleukin 19 level in patients with warts;AIMS Molecular Science;2023

2. IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism;Cells;2021-12-13

3. Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cells;Cytokine;2021-08

4. Features of interleukin-19 production in patients with atherosclerosis;The Siberian Journal of Clinical and Experimental Medicine;2021-07-07

5. Probiotic lactobacilli as a promising strategy to ameliorate disorders associated with intestinal inflammation induced by a non-steroidal anti-inflammatory drug;Scientific Reports;2021-01-12